"going into battle is like baking a cake. 1ST you need a battle plan"....Julia Childs
4. Well you got your wish Opti...down 7% on low volume sparce trades. A hedgefund's wet dream come true. Just sayin.
1. since when are phase 1 studies on animal groups no longer the norm?
2. one patient indicated 90% efficacy. Why couldn't this transfer to a much larger cohort. Proof of concept has been indicated,
3. you are speculating that was the reason behind the private financing. Only conjecture at this point.
4. SKS has a complete lab dept. working on eye disease...what better an addition to OHRP
5. Partnerships only happen when data is released, rarely bfr.
We could see another rally into June getting ready for 90% efficacy results. Confidence rally followed by partnership on much more favourable terms to OHRP after they show their stuff. They can afford to shop around with their financing. Not many shares out there left to short Opti. Better get working than just saying.
Thanx Irish...appreciate the update. I`m glad that John is doing so well. Scarlet should have had you present this at the last CC.
Always the best news on this board, deserving of a 21 Shamrock rating
1. Squalamine rabbit topical studies had produced highly significant p values supporting efficacy in broadly confident 7 &14 day intervals
2. Elman's PDR patient had monotherapy without rescue injections/ patient X responded to the eye drops, needing no injections for 6 months raises the probability that it could treat most wet amd to a level of at least 90%.
3. the recent PIPE enables enough financing to take squalamine through phase II finishing in 9 months and on to phase III. Positive
4. recently acquired SKS gives them an in-house biotech team ready to advance Squalamine's clinical pathway wrt AMD, diabetic retinopathy, retinal vein occlusions and macular edema.
5. also down the pipeline is OHR/AVR 118, a Phase II clinical trial product for the treatment of cancer cachexia. In addition, OHRP owns various other compounds in earlier stages of development, including the PTP1b inhibitor trodusquemine and related analogs . This is not a one trick pony setting up for a quick pump & dump.
OPTI's BOARD "we keep it real" ...if you call bashing 24/7 based on your baseless conjectures keeping it real, I hardly think so. Your agenda is to short OHRP and get the SP low as possible or convince retail into selling. With a relatively small float and limited shares traded it becomes an easy target for those that make gains by creating volatility. Your handle showed up when the SP started moving up to $19.99 from which you've played puts and issued calls and although you bring up several concerns on timing, you have not brought up any concrete evidence that squalamine doesn't get to the back of the eye. Livermore has (ad nauseam) dissertated every molecular reaction in the scientific process and gives a pretty convincing argument for supporting the drug's efficacy. His trading advice was not as convincing however and only a fool would believe the lofty price targets he was putting out there. Not to subtract from his enthusiasm, given positive results and no major issues arising, a ten banger in the works is possible. You can accept it or challenge it but with your condescending bashing on anyone or argument contrary to your 'short position' you take personal aim at them or it without substance. Surprise Yahoo lets you get away with it.
Contrary to Liverwurst, if you didn't agree with him he was courteous enough to accept your opposing view. Stewy and Liverwurst would be arguing efficacy for months on end but at least they kept it civil.
You add personal insult in order to add to confrontation. Enjoy talking to yourself, by yourself on your board.
not another breakout. What with measles, camel flu, west nile and now chikungunya I'm not sure if I can take it on the gerny.
Am I reading this right? Optimist chastising someone for bashing OHRP.
"your stock" makes it sound like it's no longer yours?
My guess is they plan a bear raid after approval news...this stock is heavily gamed. I may take some off during this next rally.
30 day period on any material event, given the time the company is notified. An FDA release in this case would not be known by the company so insiders are allowed to base trades up to the date the release is given. No doubt a low risk move given all the events to date pointing to a partial release.
the FDA website had interim results for phase II listed as June for the last 6 months. Only change made by the company were that final results completion in 2014 has been moved to 1ST QRT 2015...most likely due to later trial intake completion (announced earlier this month) Happens all the time in trials. If the trials prove proof positive for Squalamine, a larger cohort study would be needed for any expedited approval process. The company so far has made all the right moves in becoming a bigger concern. Expanding a pipeline, acquiring an in house biotech specialist team yet not diluting the MC to a100 million to get there.
If one wasn't such an optimist one could never construe this as being a negative.
The MAYO Clinic has recently had a CR success treating a MM patient with a high dose of measles vaccine. MAYO's working on some interesting cures.
Well Scarlet finally just came out and said the LFT were such a low grade signal that "you wouldn't notice it unless you were looking for it". This supports what you have been telling us all along about John's response Irish and underlines the stupidity that abounds around this clinical hold. No doubt the JAK1 lobby who were first to notice and alert the FDA to take procedural protocol wrt Hy's Law when in fact this 'slight' elevation appeared to have been overlooked a year or so ago by the FDA ( deemed as insignificant at the time) after receiving previous ET trial data submission. This sudden immediacy on the part of the FDA a considerable time after the fact points to some complicity wrt to the timing of the FDA's hold response. Why now? The irony is that if Jak1 was applying in today's environment based on their limited efficacy and serious side effects they would never had made the FDA grade of approval.
...all that's been presented to date supports Squalamine's efficacy dble blinded or not. What results have been discussed are not typical of placebo interaction. With these types of trials results are many a time a forgone conclusion than not.
I say never say never. As SP returns to where it reflects the potential market on Squalamine, now with a fully credited team behind them less optimistic posters will gradually disappear. These board can be a battle ground but no need to isolate oneself in a bubble room. All views are of value. As unfounded claims are proven wrong we shall see shorts covering soon bfr. they get too soiled.